We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$11.9M
Cap. Flow
+$42.8M
Cap. Flow %
11.33%
Top 10 Hldgs %
55.17%
Holding
61
New
9
Increased
14
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.7M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$10.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.5M
4
HALO icon
Halozyme
HALO
+$12.5M
5
AMGN icon
Amgen
AMGN
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
51
Axsome Therapeutics
AXSM
$10.8B
$793K 0.21%
14,000
– –
KYNB
52
Kyntra Bio
KYNB
$32.4M
$684K 0.18%
788
– –
TVTX icon
53
Travere Therapeutics
TVTX
$6.36B
$499K 0.13%
20,000
– –
BLUE
54
DELISTED
bluebird bio
BLUE
$332K 0.09%
849
– –
ESPR
55
DELISTED
Esperion Therapeutics
ESPR
$266K 0.07%
9,500
– –
ANAB icon
56
AnaptysBio
ANAB
$1.7B
$216K 0.06%
10,000
– –
MRSN
57
DELISTED
Mersana Therapeutics
MRSN
– –
-2,880
Closed -$1.91M
ZEAL
58
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
– –
-5,653
Closed -$203K
ALXN
59
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-99,241
Closed -$15.5M
GWPH
60
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-10,200
Closed -$1.18M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2021 Portfolio in Review

As of Q1 2021, International Biotechnology Trust held 61 positions worth $378M, up 3.3% from $366M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

International Biotechnology Trust deployed $42.8M of net new capital in Q1 2021, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Illumina: 16,756 shares worth $6.26M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $18.8M trimmed.

  • International Biotechnology Trust's largest Q1 2021 buy was Illumina: 16,756 shares worth $6.26M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2021, an estimated $19.2M increase.
  • International Biotechnology Trust's biggest Q1 2021 reduction was Acadia Pharmaceuticals, cutting an estimated $18.8M.
  • International Biotechnology Trust fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $15.5M.
  • International Biotechnology Trust's ten largest holdings make up 55% of its $378M portfolio in Q1 2021.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q1 2021.
  • International Biotechnology Trust's portfolio value rose 3.3% quarter-over-quarter to $378M.

Based on International Biotechnology Trust's 13F filing for Q1 2021, filed 17 May 2021.